AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02947022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc DTPA
Description: On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.
Study NCT01574144 — intervention group
Intervention type: DEVICE
Intervention: AVIVO™ PiiX Patch Monitor System
Description: External monitoring for 30 days post-discharge.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical aneurysmal operating techniques
Description: The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microsurgical aneurysmal operating techniques
Description: The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular techniques for cerebrovascular stenosis
Description: The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endovascular techniques for cerebrovascular stenosis
Description: The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
Study NCT03678558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytochalasin B supplemented vitrification medium
Description: Vitrification of human oocyte in medium supplemented with Cytochalasin B
Study NCT01238744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed drink
Description: Drink containing flaxseed mucilage
Study NCT01238744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed drink
Description: Drink containing flaxseed mucilage
Study NCT01238744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed tablet
Description: Tablets containing flaxseed mucilage consumed with a control drink
Study NCT01238744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: Control drink
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine (ZDV)
Description: 300 mg twice daily
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (NVP): Antepartum Mothers
Description: 200 mg at onset of labor
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular techniques for intracranial aneurysms
Description: The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endovascular techniques for intracranial aneurysms
Description: The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid endarterectomy
Description: A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
Study NCT03204435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: carotid endarterectomy
Description: A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
Study NCT00469638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial catheter ablation guided by introducer using Agilis sheeth
Description: Left atrial catheter ablation guided by introducer using Agilis sheeth
Study NCT00469638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial catheter ablation guided by introducer using Non-steerable sheeth
Description: Left atrial catheter ablation guided by introducer using Non-steerable sheeth
Study NCT01770691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPI vaginal pessary
Description: TIPI vaginal pessary G3 model, and TIPI SMD's
Study NCT01935336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45mg taken by mouth each day at the same time with or without food
Study NCT00050986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
Description: 200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine-Zidovudine (3TC-ZDV)
Description: 150 mg/300 mg twice daily
Study NCT00050986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R115777
Description: Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
Study NCT02178293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzidamine hydrochloride
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-RTV)
Description: 400 mg/100 mg twice daily beginning at >= 14 weeks gestation; 600 mg/150 mg twice daily beginning at >= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
Study NCT02178293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt
Study NCT04259138 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Treatment Algorithm C
Description: Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])
Description: 200 mg/300 mg
Study NCT03186703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored knowledge translation
Description: Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
Study NCT00551382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muntelukast
Description: Tablets or granules; 4 mg once a day for 12 weeks
Study NCT00551382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look alike tablets or granules 1 per day for 12 weeks
Study NCT03852459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ibuprofen
Description: Topical Gel 5%
Study NCT03852459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel
Study NCT01565772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: 45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (NVP): Infant short-course
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
Study NCT01565772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m2 IV on days 1, 8 of cycles 1 and 2
Study NCT01565772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2 IV on days 1-5 on Cycles 1-2
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP): Infant short-course
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
Study NCT01061151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP): Infant extended
Description: Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
Study NCT01061151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail.
Study NCT01061151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue triple ARVs
Description: ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
Study NCT01061151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continue triple ARVs
Description: Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
Study NCT01684150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZ-5676
Description: MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
Study NCT04207294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pork arm
Description: The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
Study NCT04207294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pork arm
Description: The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
Study NCT04207294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork arm
Description: The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
Study NCT01720030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Verum therapy
Study NCT04207294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chicken arm
Description: The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
Study NCT04207294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chicken arm
Description: The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
Study NCT02082548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
Study NCT00827346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg now
Study NCT00827346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg now and 600 mg in 3 hours
Study NCT00827346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 900 mg now
Study NCT00827346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg now and 300 mg in 3 hours
Study NCT02019524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide vaccine
Description: 500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
Study NCT02019524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 vaccine then J65 vaccine
Description: The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Study NCT02019524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: J65 vaccine then E39 vaccine
Description: The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Study NCT02542917 — intervention group
Intervention type: DEVICE
Intervention: IBDoc home test for faecal calprotectin
Description: IBDoc home test for faecal calprotectin
Study NCT04416126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
Study NCT04416126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is 0.9% sterile saline.
Study NCT02737735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy medicine combined with Chinese herbs
Study NCT02737735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy medicine
Study NCT01720030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional therapy
Description: Placebo therapy to safeguard blinding
Study NCT03793621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: single rising oral dose
Study NCT03793621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single rising oral dose
Study NCT03961906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
Study NCT00602693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Infusion of umbilical cord blood
Study NCT00602693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
Study NCT02709083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given orally
Study NCT02709083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given orally
Study NCT02709083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given orally
Study NCT02525419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Phase
Description: High Protein, Intermittent Fast, Low Calorie Diet
Study NCT02525419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HP-IF
Description: High Protein, Intermittent Fast
Study NCT02525419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HH
Description: Heart Healthy
Study NCT01844830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Intranasally administered regional anesthetic
Study NCT01844830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients supplied in identical nasal sprayer
Study NCT02327221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovasave
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Study NCT02327221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Study NCT02170649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT02500602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin
Description: active medication
Study NCT02500602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill
Study NCT01319786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
Description: Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
Study NCT00602693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
Study NCT00996021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 250 mg
Description: This is an experimental HIV medication in the integrase inhibitor class.
Study NCT00996021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Suspension
Description: Placebo is a liquid with no drug in it.
Study NCT00996021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: This is an FDA approved antibiotic in the fluoroquinolone class.
Study NCT04385615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
Study NCT01319786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
Description: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
Study NCT04486755 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
Study NCT02341833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
Study NCT01157897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VMP001
Description: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
Study NCT01157897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P. vivax sporozoite challenge
Description: P. vivax sporozoite challenge